Egalet buys in two innovative approved pain products, Oxaydo and Sprix

US biotech firm Egalet Corp (Nasdaq: EGLT) has in-licensing two innovative approved pain products transforming Egalet into a fully integrated specialty pharmaceutical company focused on developing and commercializing products indicated to treat patients living with moderate to severe pain.

Egalet has agreed to license worldwide rights to Oxaydo (oxycodone HCI, USP) tablets for oral use only - CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting from US specialty pharma firm Acura Pharmaceuticals (Nasdaq: ACUR). Oxaydo is approved in the USA and is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

In addition, Egalet has acquired Sprix (ketorolac tromethamine) Nasal Spray from Luitpold Pharmaceuticals, a subsidiary of Japan’s Daiichi Sankyo (TKO: 4568). Sprix is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that requires analgesia at the opioid level. With the addition of these two products, Egalet plans to build a commercial infrastructure that will help pave the way for the launch of Egalet's late-stage pipeline of abuse-deterrent opioids.